dQM QICore Content Implementation Guide
2025.0.0 - CI Build
dQM QICore Content Implementation Guide, published by cqframework. This guide is not an authorized publication; it is the continuous build for version 2025.0.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/cqframework/dqm-content-qicore-2025/ and changes regularly. See the Directory of published versions
Official URL: https://madie.cms.gov/Measure/CMS645FHIRBoneDensityPCADTherapy | Version: 1.0.000 | |||
Active as of 2025-08-22 | Responsible: Oregon Urology | Computable Name: CMS645FHIRBoneDensityPCADTherapy | ||
Other Identifiers: Short Name: CMS645FHIR (use: usual, ), UUID:299de9c4-755d-4f5a-ac9e-fa74fe34f759 (use: official, ), UUID:5cd769d8-9a63-4637-b18e-76ee9c68cbf9 (use: official, ), Publisher: 645FHIR (use: official, ) | ||||
Copyright/Legal: Limited proprietary coding is contained in the measure specifications for convenience. Users of the proprietary code sets should obtain all necessary licenses from the owners of these code sets. Oregon Urology Institute (OUI) and Large Urology Group Practice Association (LUGPA) disclaim all liability for the use or accuracy of third-party codes contained in the specifications. CPT(R) contained in the Measure specifications is copyright 2004-2024. American Medical Association. LOINC(R) copyright 2004-2024 Regenstrief Institute, Inc. This material contains SNOMED Clinical Terms(R) (SNOMED CT[R]) copyright 2004-2024. International Health Terminology Standards Development Organisation. ICD-10 copyright 2024 World Health Organization. All Rights Reserved. |
Percentage of patients determined as having prostate cancer who are currently starting or undergoing androgen deprivation therapy (ADT), for an anticipated period of 12 months or greater and who receive an initial bone density evaluation. The bone density evaluation must be prior to the start of ADT or within 3 months of the start of ADT.
Metadata | |
---|---|
Title | Bone Density Evaluation for Patients with Prostate Cancer and Receiving Androgen Deprivation TherapyFHIR |
Version | 1.0.000 |
Short Name | CMS645FHIR |
GUID (Version Independent) | urn:uuid:299de9c4-755d-4f5a-ac9e-fa74fe34f759 |
GUID (Version Specific) | urn:uuid:5cd769d8-9a63-4637-b18e-76ee9c68cbf9 |
CMS Identifier | 645FHIR |
Effective Period | 2026-01-01 through 2026-12-31 |
Steward (Publisher) | Oregon Urology |
Developer | Oregon Urology |
Description | Percentage of patients determined as having prostate cancer who are currently starting or undergoing androgen deprivation therapy (ADT), for an anticipated period of 12 months or greater and who receive an initial bone density evaluation. The bone density evaluation must be prior to the start of ADT or within 3 months of the start of ADT. |
Copyright | Limited proprietary coding is contained in the measure specifications for convenience. Users of the proprietary code sets should obtain all necessary licenses from the owners of these code sets. Oregon Urology Institute (OUI) and Large Urology Group Practice Association (LUGPA) disclaim all liability for the use or accuracy of third-party codes contained in the specifications. CPT(R) contained in the Measure specifications is copyright 2004-2024. American Medical Association. LOINC(R) copyright 2004-2024 Regenstrief Institute, Inc. This material contains SNOMED Clinical Terms(R) (SNOMED CT[R]) copyright 2004-2024. International Health Terminology Standards Development Organisation. ICD-10 copyright 2024 World Health Organization. All Rights Reserved. |
Disclaimer | The performance measure is not a clinical guideline and does not establish a standard of medical care, and has not been tested for all potential applications. THE MEASURES AND SPECIFICATIONS ARE PROVIDED "AS IS" WITHOUT WARRANTY OF ANY KIND. Due to technical limitations, registered trademarks are indicated by (R) or [R] and unregistered trademarks are indicated by (TM) or [TM]. |
Rationale | Androgen suppression as a treatment for prostate cancer can cause osteoporosis (Qaseem, 2008). Patients with prostate cancer undergoing prolonged androgen deprivation therapy (ADT) incur bone loss at a rate higher than menopausal patients (Guise, 2007). In preserving bone health, the goal is to prevent or treat osteopenia/osteoporosis for the patient on ADT and to prevent or delay skeletal-related events. The National Osteoporosis Foundation recommendations include a baseline assessment of bone density with a dual-energy X-ray absorptiometry (DEXA) scan and daily calcium and Vitamin D supplementation (Watts, 2012). The DEXA scan is the gold standard for bone density screening. Patients at risk for adverse bone consequences from chronic ADT do not always receive care according to evidence-based guidelines. These findings call for improved processes that standardize evidence-based practice, including baseline and follow-up bone density assessment (Watts, 2012). |
Clinical Recommendation Statement | Bone density screening should be performed at the start of Androgen Deprivation Therapy (ADT) for prostate cancer. It should also be performed every 2 years for the patient with continued ADT or for patients with known osteoporosis. Current insurance practice is to possibly cover the cost of bone density screening if osteoporosis is known or if there is a high-risk drug. Some patients choose to delay bone density screening until after ADT is started and they therefore have insurance authorization due to the administration of a high-risk drug. |
Citation |
Cosman, F., deBeur, S.J., LeBoff, M.S., Lewiecki, E. M., Tanner, B., Randall, S., & Lindsay, R. (2014). Clinician’s Guide to Prevention and Treatment of Osteoporosis. Osteoporosis International, 25(10), 2359–2381. https://doi.org/10.1007/s00198-014-2794-2 |
Citation |
Finkelstein, J., & Yu, E. (2017). Clinical manifestations, diagnosis, and evaluation of osteoporosis in men. Retrieved from https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-evaluation-of-osteoporosis-in-men/print?source=see_link |
Citation |
Guise, T.A., Oefelein, M.G., Eastham, J.A., Cookson, M.S., Higano, C.S., & Smith, M.R. (2007). Estrogenic side effects of androgen deprivation therapy. Reviews in urology, 9(4), 163-180. |
Citation |
Qaseem, A., Snow, V., Shekelle, P., Hopkins, R., Forciea, M. A., Owens, D. K., & for the Clinical Efficacy Assessment Subcommittee of the American College of Physicians. (2008). Annals of Internal Medicine. Screening for osteoporosis in men: A clinical practice guideline from the American College of Physicians, 2008. Annals of Internal Medicine, 148(9), 680-684. https://doi.org/10.7326/0003-4819-148-9-200805060-00008 |
Citation |
Ward, R. J., Roberts, C. C., Bencardino, J. T., Arnold, E., Baccei, S. J., Cassidy, R. C., … Weissman, B. N. (2017). ACR Appropriateness Criteria (R) Osteoporosis and Bone Mineral Density. Journal of the American College of Radiology, 14(5), S189–S202. https://doi.org/10.1016/j.jacr.2017.02.018 |
Citation |
Watts, N. B., Adler, R. A., Bilezikian, J. P., Drake, M. T., Eastell, R., Orwoll, E. S., & Finkelstein, J. S. (2012). Osteoporosis in Men: An Endocrine Society Clinical Practice Guideline. The Journal of Clinical Endocrinology & Metabolism, 97(6), 1802–1822. https://doi.org/10.1210/jc.2011-3045 |
Definition | Dual Energy X-ray Absorptiometry (DEXA): A scan that measures the bone of the spine, hip, or total body and measures bone mineral density. It is considered one of the most accurate measurements. |
Definition | First Androgen Deprivation Therapy: The first Androgen Deprivation Therapy (ADT) is measured as the first order or administration of ADT for an anticipated period of 12 months or greater to a patient with prostate cancer. |
Definition | Peripheral Dual Energy X-ray Absorptiometry (PDXA): Bone mineral density measurement of the wrist, heel, or finger. |
Guidance (Usage) | In order to capture the practitioner's intent of androgen deprivation therapy (ADT) for a period of 12 months or greater, SNOMEDCT 456381000124102 which is Injection of leuprolide acetate for the twelve-month period (regime/therapy) is the correct code. This eCQM is a patient-based measure. This FHIR-based measure has been derived from the QDM-based measure CMS645v9. Please refer to the HL7 QI-Core Implementation Guide (https://hl7.org/fhir/us/qicore/STU6/) for more information on QI-Core and mapping recommendations from QDM to QI-Core STU 6 (https://hl7.org/fhir/us/qicore/STU6/qdm-to-qicore.html). |
Measure Group (Rate) (ID: Group_1) | |
Basis | boolean |
Scoring | [http://terminology.hl7.org/CodeSystem/measure-scoring#proportion: 'Proportion'] |
Type | [http://terminology.hl7.org/CodeSystem/measure-type#process: 'Process'] |
Improvement Notation | [http://terminology.hl7.org/CodeSystem/measure-improvement-notation#increase: 'Increased score indicates improvement'] |
Initial Population |
ID: InitialPopulation_1
Description: Patients with a qualifying encounter in the measurement period AND with a diagnosis of prostate cancer AND with an order for ADT or an active medication of ADT with an intent for treatment greater than or equal to 12 months during the measurement period AND order for ADT in 3 months before to 9 months after the start of the measurement period Logic Definition: Initial Population |
Denominator |
ID: Denominator_1
Description: Equals Initial Population Logic Definition: Denominator |
Numerator |
ID: Numerator_1
Description: Patients with a bone density evaluation within the two years prior to the start of or less than three months after the start of ADT treatment Logic Definition: Numerator |
Denominator Exception |
ID: DenominatorException_1
Description: Patient refused the bone density evaluation at the time ordered or did not have it performed within 3 months after the start of ADT Logic Definition: Denominator Exception |
Supplemental Data Guidance | For every patient evaluated by this measure also identify payer, race, ethnicity and sex |
Supplemental Data Elements | |
Supplemental Data Element |
ID: sde-ethnicity
Usage Code: [http://terminology.hl7.org/CodeSystem/measure-data-usage#supplemental-data] Description: SDE Ethnicity Logic Definition: SDE Ethnicity |
Supplemental Data Element |
ID: sde-payer
Usage Code: [http://terminology.hl7.org/CodeSystem/measure-data-usage#supplemental-data] Description: SDE Payer Logic Definition: SDE Payer |
Supplemental Data Element |
ID: sde-race
Usage Code: [http://terminology.hl7.org/CodeSystem/measure-data-usage#supplemental-data] Description: SDE Race Logic Definition: SDE Race |
Supplemental Data Element |
ID: sde-sex
Usage Code: [http://terminology.hl7.org/CodeSystem/measure-data-usage#supplemental-data] Description: SDE Sex Logic Definition: SDE Sex |
Measure Logic | |
Primary Library | https://madie.cms.gov/Library/CMS645FHIRBoneDensityPCADTherapy |
Contents |
Population Criteria
Logic Definitions Terminology Dependencies Data Requirements |
Population Criteria | |
Measure Group (Rate) (ID: Group_1) | |
Initial Population | |
|
|
Denominator | |
|
|
Numerator | |
|
|
Denominator Exception | |
|
|
Logic Definitions | |
Logic Definition | Library Name: SupplementalDataElements |
|
|
Logic Definition | Library Name: SupplementalDataElements |
|
|
Logic Definition | Library Name: SupplementalDataElements |
|
|
Logic Definition | Library Name: SupplementalDataElements |
|
|
Logic Definition | Library Name: CMS645FHIRBoneDensityPCADTherapy |
|
|
Logic Definition | Library Name: CMS645FHIRBoneDensityPCADTherapy |
|
|
Logic Definition | Library Name: CMS645FHIRBoneDensityPCADTherapy |
|
|
Logic Definition | Library Name: CMS645FHIRBoneDensityPCADTherapy |
|
|
Logic Definition | Library Name: CMS645FHIRBoneDensityPCADTherapy |
|
|
Logic Definition | Library Name: CMS645FHIRBoneDensityPCADTherapy |
|
|
Logic Definition | Library Name: CMS645FHIRBoneDensityPCADTherapy |
|
|
Logic Definition | Library Name: CMS645FHIRBoneDensityPCADTherapy |
|
|
Logic Definition | Library Name: CMS645FHIRBoneDensityPCADTherapy |
|
|
Logic Definition | Library Name: CMS645FHIRBoneDensityPCADTherapy |
|
|
Logic Definition | Library Name: CMS645FHIRBoneDensityPCADTherapy |
|
|
Logic Definition | Library Name: CMS645FHIRBoneDensityPCADTherapy |
|
|
Logic Definition | Library Name: CMS645FHIRBoneDensityPCADTherapy |
|
|
Logic Definition | Library Name: CMS645FHIRBoneDensityPCADTherapy |
|
|
Logic Definition | Library Name: CMS645FHIRBoneDensityPCADTherapy |
|
|
Logic Definition | Library Name: CMS645FHIRBoneDensityPCADTherapy |
|
|
Logic Definition | Library Name: CMS645FHIRBoneDensityPCADTherapy |
|
|
Logic Definition | Library Name: FHIRHelpers |
|
|
Logic Definition | Library Name: FHIRHelpers |
|
|
Logic Definition | Library Name: FHIRHelpers |
|
|
Terminology | |
Code System |
Description: Code system SNOMEDCT
Resource: http://snomed.info/sct Canonical URL: http://snomed.info/sct |
Value Set |
Description: Value set DEXA Bone Density for Urology Care
Resource: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.359 Canonical URL: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.359 |
Value Set |
Description: Value set Androgen Deprivation Therapy for Urology Care
Resource: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.352 Canonical URL: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.352 |
Value Set |
Description: Value set Prostate Cancer
Resource: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.319 Canonical URL: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.319 |
Value Set |
Description: Value set Patient Declined
Resource: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1582 Canonical URL: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1582 |
Value Set |
Description: Value set Office Visit
Resource: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.12.1001 Canonical URL: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.12.1001 |
Value Set |
Description: Value set Payer Type
Resource: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3591 Canonical URL: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3591 |
Direct Reference Code |
Display: Male (finding)
Code: 248153007 System: http://snomed.info/sct |
Direct Reference Code |
Display: Female (finding)
Code: 248152002 System: http://snomed.info/sct |
Direct Reference Code |
Display: Injection of leuprolide acetate for twelve month period (regime/therapy)
Code: 456381000124102 System: http://snomed.info/sct |
Dependencies | |
Dependency |
Description: QICore model information
Resource: http://hl7.org/fhir/Library/QICore-ModelInfo Canonical URL: http://hl7.org/fhir/Library/QICore-ModelInfo |
Dependency |
Description: Library SDE
Resource: https://madie.cms.gov/Library/SupplementalDataElements|5.1.000 Canonical URL: https://madie.cms.gov/Library/SupplementalDataElements|5.1.000 |
Dependency |
Description: Library FHIRHelpers
Resource: https://madie.cms.gov/Library/FHIRHelpers|4.4.000 Canonical URL: https://madie.cms.gov/Library/FHIRHelpers|4.4.000 |
Dependency |
Description: Library QICoreCommon
Resource: https://madie.cms.gov/Library/QICoreCommon|4.0.000 Canonical URL: https://madie.cms.gov/Library/QICoreCommon|4.0.000 |
Data Requirements | |
Data Requirement |
Type: Patient
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-patient Must Support Elements: extension, url |
Data Requirement |
Type: MedicationRequest
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-medicationrequest Must Support Elements: medication, dosageInstruction, status, status.value, intent, intent.value, authoredOn, authoredOn.value Code Filter(s): Path: medication ValueSet: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.352 |
Data Requirement |
Type: MedicationRequest
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-medicationrequest Must Support Elements: medication.reference.value, dosageInstruction, status, status.value, intent, intent.value, authoredOn, authoredOn.value |
Data Requirement |
Type: Medication
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-medication Must Support Elements: id.value, code |
Data Requirement |
Type: Condition
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-condition-problems-health-concerns Must Support Elements: code Code Filter(s): Path: code ValueSet: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.319 |
Data Requirement |
Type: Condition
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-condition-encounter-diagnosis Must Support Elements: code Code Filter(s): Path: code ValueSet: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.319 |
Data Requirement |
Type: ServiceRequest
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-servicerequest Must Support Elements: code, authoredOn, authoredOn.value, status, status.value, intent, intent.value Code Filter(s): Path: code Code(s): http://snomed.info/sct#456381000124102: 'Injection of leuprolide acetate for twelve month period (regime/therapy)' |
Data Requirement |
Type: ServiceRequest
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-servicerequest Must Support Elements: code, authoredOn, authoredOn.value, status, status.value, intent, intent.value Code Filter(s): Path: code ValueSet: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.359 |
Data Requirement |
Type: Observation
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-observation-clinical-result Must Support Elements: code, effective, status, status.value Code Filter(s): Path: code ValueSet: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.359 |
Data Requirement |
Type: ServiceRequest
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-servicenotrequested Must Support Elements: code, authoredOn, authoredOn.value, extension Code Filter(s): Path: code ValueSet: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.359 |
Data Requirement |
Type: Observation
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-observationcancelled Must Support Elements: code, issued, issued.value, extension Code Filter(s): Path: code ValueSet: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.359 |
Data Requirement |
Type: Encounter
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-encounter Must Support Elements: type, period, status, status.value Code Filter(s): Path: type ValueSet: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.12.1001 |
Data Requirement |
Type: Coverage
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-coverage Must Support Elements: type, period Code Filter(s): Path: type ValueSet: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3591 |
Generated using version 0.4.8 of the sample-content-ig Liquid templates |